Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...
Everyday Health on MSN
There’s a new drug for motion sickness — the first in 40 years
The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side ...
Stocktwits on MSN
VNDA stock on track to open at three-year high – FDA clears first new motion sickness drug in decades
Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo. ・Vanda is also advancing Tradipitant in clinical development for ...
Does motion sickness turn you into a green, spewing mess? For plenty of people, the answer is yes. Current remedies may or ...
FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...
Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion.
The FDA has approved tradipitant (Nereus), an oral NK-1 receptor antagonist, for preventing motion-induced vomiting in adults. This marks the first new treatment for motion sickness in over ...
Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...
Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback